Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

JANX Janux Therapeutics, Inc.

交易中 08-04 13:03:21 EDT

15.87

+0.55

+3.56%

最高15.87	最低15.35	成交量16.76万
今开15.42	昨收15.32	日振幅3.39%
总市值9.65亿	流通市值6.21亿	总股本6,083万
成交额262.47万	换手率0.43%	流通股本3,913万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"JANX","market":"US","secType":"STK","nameCN":"Janux Therapeutics, Inc.","latestPrice":15.865,"timestamp":1785862999770,"preClose":15.32,"halted":0,"volume":167599,"delay":0,"changeRate":0.03557441253263707,"floatShares":39133300,"shares":60831656,"eps":-1.833637,"marketStatus":"交易中","change":0.545,"latestTime":"08-04 13:03:21 EDT","open":15.42,"high":15.865,"low":15.345,"amount":2624675.256753,"amplitude":0.033943,"askPrice":15.86,"askSize":203,"bidPrice":15.85,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-1.833637,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785873600000},"marketStatusCode":2,"adr":0,"listingDate":1623384000000,"exchange":"NASDAQ","adjPreClose":15.32,"preHourTrading":{"tag":"盘前","latestPrice":15.45,"preClose":15.32,"latestTime":"09:29 EDT","volume":245,"amount":3783.799355,"timestamp":1785850199999,"change":0.13,"changeRate":0.008486,"amplitude":0.022226},"postHourTrading":{"tag":"盘后","latestPrice":15.32,"preClose":15.32,"latestTime":"19:34 EDT","volume":21558,"amount":330277.06,"timestamp":1785800047166,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.501149,"impliedVol":0.5216,"impliedVolPercentile":0.1116},"requestUrl":"/m/hq/s/JANX","defaultTab":"news","newsList":[{"id":"1104893018","title":"Janux Therapeutics公司有望获得额外里程碑付款及全球销售分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1104893018","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104893018?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:04","pubTimestamp":1775045067,"startTime":"0","endTime":"0","summary":"Janux Therapeutics公司（简称JANX）宣布，其根据合作协议条款，现具备资格获得额外的里程碑付款。此外，该公司还将享有基于全球销售额的分层特许权使用费。\n这一进展标志着Janux在业务发展和商业化道路上迈出了重要一步。额外的财务激励将为其研发活动提供进一步支持，同时分层 royalties 结构也体现了其创新成果的市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127668490","title":"Janux Therapeutics与百时美施贵宝合作提名开发候选药物，触发3500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1127668490","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127668490?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:03","pubTimestamp":1775044995,"startTime":"0","endTime":"0","summary":"Janux Therapeutics, Inc.宣布，在与百时美施贵宝的合作框架下，已正式提名一项开发候选药物。这一进展触发了合作协议中约定的3500万美元里程碑付款条款。\n此次候选药物的提名标志着双方在肿瘤免疫治疗领域的合作取得实质性突破。该里程碑付款的兑现，将进一步支持Janux Therapeutics推进其创新疗法管线的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605149493","title":"生物制药公司Janux Therapeutics与施贵宝达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2605149493","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605149493?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:47","pubTimestamp":1769089661,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0002141913.USD","LU0061475181.USD","LU1323610961.USD","BK4534","BK4007","LENZ","LU1261432733.SGD","LU1989771016.USD","LU0321505439.SGD","LU1074936037.SGD","LU0096364046.USD","LU0306806265.USD","LU2125154935.USD","LU1868836914.USD","LU1868837300.USD","LU0456855351.SGD","IE00B2B36J28.USD","LU1718418525.SGD","BMY","LU0237698245.USD","LU1868837136.USD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU2242646821.SGD","LU1670710588.SGD","LU1430594728.SGD","LU2242652126.USD","IE00BFXG1179.USD","LU1585245621.USD","LU0225284248.USD","LU1670711123.USD","LU0114720955.EUR","LU0868494617.USD","LU1093756168.USD","LU0306807586.USD","BK4539","BK4139","LU1868836591.USD","LU1670710661.SGD","BK4559","LU1291159041.SGD","LU0225771236.USD","BK4588","LU0985481810.HKD","IE0009355771.USD","BK4585","LU1571399168.USD","JANX","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150021627","title":"Janux Therapeutics股价盘前飙升14.5% 与百时美施贵宝达成癌症药物开发全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1150021627","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150021627?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:16","pubTimestamp":1769084184,"startTime":"0","endTime":"0","summary":"Janux Therapeutics, Inc. (JANX) 股价在盘前交易中大幅跃升14.5%，此前该公司宣布与制药巨头百时美施贵宝（Bristol Myers Squibb）就癌症药物开发项目达成了一项全球授权协议。\n此项合作旨在利用Janux Therapeutics的创新技术平台，共同推进新型癌症疗法的研发进程。市场对此消息反应积极，显示出投资者对此次强强联合及其在肿瘤治疗领域潜力的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106509089","title":"Janux Therapeutics与百时美施贵宝达成合作：后者将主导新药临床试验申请及后续全球开发商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1106509089","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106509089?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:09","pubTimestamp":1769083778,"startTime":"0","endTime":"0","summary":"根据最新合作协议框架，Janux Therapeutics, Inc. 与百时美施贵宝已明确分工：百时美施贵宝将全面负责新药临床试验申请的提交工作，并主导后续所有开发阶段及全球商业化布局。这一合作模式凸显了双方在创新药物领域的战略协同，预计将加速相关疗法的研发进程与市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107112538","title":"Janux Therapeutics, Inc. 将完成临床前开发至新药临床试验申请阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1107112538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107112538?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:06","pubTimestamp":1769083585,"startTime":"0","endTime":"0","summary":"作为合作计划的一部分，Janux Therapeutics, Inc. 将负责推进其项目的临床前开发工作，直至达到提交新药临床试验申请的标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198312367","title":"Janux Therapeutics有望获得总额约8亿美元的开发、监管及商业里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1198312367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198312367?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:06","pubTimestamp":1769083573,"startTime":"0","endTime":"0","summary":"根据协议条款，Janux Therapeutics, Inc.有资格获得累计最高约8亿美元的开发、监管和商业里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JANX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517430499","title":"Janux Therapeutics, Inc.2024财年实现净利润-68.99百万美元，同比减少18.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517430499?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Janux Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-68.99百万美元，同比减少18.36%；其中营业收入为10.59百万美元，同比增加31.06%，每股基本收益为-1.28美元。从资产负债表来看，Janux Therapeutics, Inc.总负债38.74百万美元，其中短期债务1.75百万美元，资产负债比为0.28，流动比率为0.60。机构评级：截至2025年3月8日，当前有13家机构对Janux Therapeutics, Inc.目标价做出预测，其中目标均价为86.54美元，其中最低目标价为25.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517694882","title":"Janux Therapeutics, Inc.盘中异动 早盘急速拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517694882?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:39","pubTimestamp":1741185583,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时39分，Janux Therapeutics, Inc.股票出现波动，股价急速上涨5.47%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223944a260ca65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223944a260ca65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516589677","title":"Janux Therapeutics, Inc.盘中异动 早盘大幅跳水5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516589677?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:31","pubTimestamp":1741098719,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时31分，Janux Therapeutics, Inc.股票出现异动，股价大幅跳水5.28%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223159a25f0476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223159a25f0476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516585562","title":"Scotiabank：维持Janux Therapeutics(JANX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由62.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516585562","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516585562?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:47","pubTimestamp":1740786423,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Janux Therapeutics(JANX.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由62.00美元调整至41.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01074748470501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","JANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136124682","title":"Janux Therapeutics 2024年第四季度GAAP每股收益$(0.36) 超出预期$(0.47)","url":"https://stock-news.laohu8.com/highlight/detail?id=1136124682","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136124682?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692305,"startTime":"0","endTime":"0","summary":"Janux Therapeutics  报告季度每股亏损$，超出分析师一致预期的$，超过23.4%。相比去年同期每股亏损$，这是一个44%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Janux $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 23.4 percent. This is a 44 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","JANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513576720","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513576720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513576720?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:54","pubTimestamp":1740408845,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时54分，Janux Therapeutics, Inc.股票出现波动，股价大幅下跌5.03%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为136.18%、55.56%、25.06%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225406962e9e7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225406962e9e7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JANX","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509238049","title":"Janux Therapeutics, Inc.盘中异动 早盘急速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509238049","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509238049?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:44","pubTimestamp":1738770244,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时44分，Janux Therapeutics, Inc.股票出现异动，股价急速拉升5.06%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.45%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Oragenics Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为4054.20%、1197.54%、978.89%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为86.20%、59.80%、54.05%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205234405abc38da0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205234405abc38da0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508835463","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大跌5.25%报39.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508835463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508835463?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:23","pubTimestamp":1738682607,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时23分，Janux Therapeutics, Inc.股票出现异动，股价大幅下挫5.25%。截至发稿，该股报39.86美元/股，成交量20.2631万股，换手率0.35%，振幅5.35%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.33%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204232327abc232e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204232327abc232e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","JANX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506874303","title":"Janux Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报46.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506874303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506874303?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:42","pubTimestamp":1737988923,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时42分，Janux Therapeutics, Inc.股票出现波动，股价大幅拉升5.10%。截至发稿，该股报46.36美元/股，成交量3.2984万股，换手率0.06%，振幅6.78%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224203a2316d37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224203a2316d37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","JANX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143280520","title":"异动解读 | 生物技术公司Janux Therapeutics盘中大跌5.26%,最新财报不佳或成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1143280520","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143280520?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:34","pubTimestamp":1737052472,"startTime":"0","endTime":"0","summary":"生物技术公司Janux Therapeutics(JANX.us)今日盘中大跌5.26%,引发投资者广泛关注。根据最新财报数据,该公司净利润亏损达2806万美元,每股收益为-0.51美元,可能是导致股价下跌的主要因素之一。\n\n此外,整个生物技术行业当日呈现整体下跌态势,跌幅达0.35%,为Janux Therapeutics股价下跌增添了一些压力。不过,目前仍无其他直接相关消息可解释该股今日出现如此大幅波动。\n\n市场机构方面,在16家参与评级的分析机构中,高达88%给予该股买入评级,看好其长期发展前景。后市如何走向或将取决于公司未来的基本面表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 生物技术公司Janux Therapeutics盘中大跌5.26%,最新财报不佳或成主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["JANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504946519","title":"Janux Therapeutics, Inc.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504946519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504946519?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:18","pubTimestamp":1737051514,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日02时18分，Janux Therapeutics, Inc.股票出现波动，股价急速下挫5.08%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.35%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021834960636d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117021834960636d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","JANX","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503758308","title":"Janux Therapeutics, Inc.盘中异动 急速下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503758308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503758308?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:44","pubTimestamp":1736779470,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时44分，Janux Therapeutics, Inc.股票出现波动，股价快速下挫5.26%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132244309864d883&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132244309864d883&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502867159","title":"Janux Therapeutics, Inc.盘中异动 急速下跌5.14%报48.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502867159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502867159?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:50","pubTimestamp":1736520658,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时50分，Janux Therapeutics, Inc.股票出现异动，股价快速下跌5.14%。Janux Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.87%。Janux Therapeutics, Inc.公司简介：Janux Therapeutics Inc 是一家临床阶段的生物制药公司，基于专有的肿瘤激活 T Cell Engager 平台技术开发下一代疗法，以更好地治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110225058aba607de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110225058aba607de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","JANX","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.januxrx.com","stockEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":-0.0142},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1493},{"period":"1year","weight":-0.3497},{"period":"ytd","weight":0.1101}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":0.0173},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2187},{"period":"ytd","weight":0.1111}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Janux Therapeutics, Inc.于2017年6月27日在特拉华州注册成立。该公司是一家创新的生物制药公司，开发基于该公司专有的肿瘤激活T细胞接合器（TRACTr）平台技术的下一代疗法，以更好地治疗癌症患者。该公司最初的重点是开发一类新的T细胞接合器（TCE），该公司的主要候选产品是针对临床验证的药物靶点设计的。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.012335},{"month":2,"riseRate":0.4,"avgChangeRate":0.856876},{"month":3,"riseRate":0.2,"avgChangeRate":-0.16442},{"month":4,"riseRate":0.8,"avgChangeRate":0.145939},{"month":5,"riseRate":0.4,"avgChangeRate":-0.087929},{"month":6,"riseRate":0.6,"avgChangeRate":-0.015019},{"month":7,"riseRate":0.666667,"avgChangeRate":0.082148},{"month":8,"riseRate":0.5,"avgChangeRate":-0.029752},{"month":9,"riseRate":0.4,"avgChangeRate":-0.031046},{"month":10,"riseRate":0.8,"avgChangeRate":0.092219},{"month":11,"riseRate":0.4,"avgChangeRate":-0.026162},{"month":12,"riseRate":0.6,"avgChangeRate":-0.021325}],"exchange":"NASDAQ","name":"Janux Therapeutics, Inc.","nameEN":"Janux Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Janux Therapeutics, Inc.(JANX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Janux Therapeutics, Inc.,JANX,Janux Therapeutics, Inc.股票,Janux Therapeutics, Inc.股票老虎,Janux Therapeutics, Inc.股票老虎国际,Janux Therapeutics, Inc.行情,Janux Therapeutics, Inc.股票行情,Janux Therapeutics, Inc.股价,Janux Therapeutics, Inc.股市,Janux Therapeutics, Inc.股票价格,Janux Therapeutics, Inc.股票交易,Janux Therapeutics, Inc.股票购买,Janux Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Janux Therapeutics, Inc.(JANX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Janux Therapeutics, Inc.(JANX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}